The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

President Donald Trump’s proposed budget for fiscal year 2026 would reduce the NIH budget by nearly $18 billion.

In an interview, FDA Commissioner Marty Makary opened up about his first weeks on the job and his vision for the future.

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

The FDA has issued a complete response letter to Telix Pharmaceuticals regarding TLX101-CDx for the imaging of gliomas.

In reducing federal funding and downsizing federal health agencies, the Trump administration is impeding cancer research.

Tepylute is now supplied as a multiple-dose vial containing 100 mg of thiotepa in addition to the previously approved single-dose vial containing 15 mg.

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

The US nursing workforce remains under immense pressure due to stress, burnout, and persistent short staffing, according to a report.